Management of COPD with Clonidine

Medication Safety in COPD

• The European Respiratory Society and other guideline societies recommend avoiding beta-blocking agents, including eyedrop formulations, in COPD patients, as they can cause bronchoconstriction 1, 2
• Clonidine, an alpha-2 adrenergic agonist, does not affect bronchial smooth muscle like beta-blockers and is safe for use in COPD patients, as it works centrally to reduce sympathetic outflow rather than blocking beta-2 receptors in the airways 1
• Beta-blockers are explicitly contraindicated in all COPD severity levels, including ophthalmic formulations, according to the American Thoracic Society and other guideline societies 1, 2

Clinical Considerations for COPD Management

• The American College of Chest Physicians recommends reviewing all current medications to ensure beta-blockers are not being used in COPD patients 1
• Optimizing COPD-specific therapy with appropriate bronchodilators, such as long-acting anticholinergics and beta-2 agonists, based on disease severity is recommended by the Global Initiative for Chronic Obstructive Lung Disease 4
• Monitoring for drug interactions with COPD medications is necessary, though clonidine has no significant interactions with standard COPD therapies, according to the European Respiratory Society 1, 4